Comparative Pharmacology
Head-to-head clinical analysis: ILEVRO versus OMIDRIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILEVRO versus OMIDRIA.
ILEVRO vs OMIDRIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
OMIDRIA is a fixed-dose combination of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist that causes vasoconstriction.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
1 mL of the fixed-dose combination (ketorolac 0.45% / phenylephrine 1%) administered intracamerally as a single dose at the time of cataract surgery.
None Documented
None Documented
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
Ketorolac: terminal half-life of 5.3 hours (range 3.8-8.2 hours) in adults; phenylephrine: terminal half-life of 2-3 hours. Clinically, ketorolac's half-life supports twice-daily dosing.
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Renal elimination of ketorolac accounts for approximately 91% of the dose, with approximately 60% as unchanged drug and the remainder as metabolites; phenylephrine is primarily metabolized and excreted in urine as sulfate conjugates, with <20% excreted unchanged.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID and Mydriatic Combination